USC Dornsife News

Inspired by his father’s fight against non-Hodgkin’s lymphoma, USC Dornsife’s Remo Rohs studies the molecular nature of cancer. [2½ min read]

Microscape software is disrupting the scientific 3D imaging field, costing a fraction of the price of competitors’ products and able to run on home computers. [4 ¼ min read]

The researchers, who are based in the USC Michelson Center for Convergent Bioscience, found that gastrointestinal issues may set the novel coronavirus SARS-CoV-2 apart from other illnesses like influenza, helping doctors to diagnose it. [1½ min read]

The findings provide a clear path to uncovering new drugs to control addiction, pain and neurological disorders such as epilepsy and muscle spasticity. [2¾ min read]

An alliance between USC and global research, development and manufacturing company Agilent enables USC researchers to unravel mysteries within individual cells and develop more targeted and personalized treatments. [4½ min read]

Students attribute Fulbright opportunities to study diabetes and cancer to research experience gained at the Bridge Institute at the USC Michelson Center for Convergent Bioscience.

Researchers plan to develop new sleep disorder treatments based on new 3D models of two melatonin receptors created by an international team. The studies were published in ‘Nature’ this week. [3¼ min read]

Experts note that increasingly complex research efforts demand greater collaboration and expertise supported by the latest procedures and instrumentation. [3 min read]

The Agilent Center of Excellence in Biomolecular Characterization at the USC Michelson Center for Convergent Bioscience will facilitate leading-edge, collaborative scientific research.